121104-96-9

121104-96-9 structure

Name: Celgosivir
Chemical Name: [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate
CAS Number: 121104-96-9
Molecular Formula: C₁₂H₂₁NO₅
Molecular Weight: 259.299
Catalog: Signaling Pathways Anti-infection HCV
Create Date: 2016-02-02 15:46:50
Modify Date: 2024-01-21 21:47:05
Celgosivir (MBI 3253; MDL 28574; MX3253) is a novel α-glucosidase I inhibitor, an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope glycoproteins.[1]

Name	[(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate
Synonyms	6-O-butanoylcastanospermine UNII:895VG117HN BuCast (1S,6S,7S,8R,8aR)-1,7,8-Trihydroxyoctahydro-6-indolizinyl butyrate MX-3253 B-T 6-O-Butyryltanosopermine 6-O-Butanoyltanospermine Butanoic Acid (1S,6S,7S,8R,8aR)-Octahydro-1,7,8-trihydroxy-6-indolizinyl Ester [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate MDL 28,574 UNII-895VG117HN 6-O-butyryltanospermine (1S,6S,7S,8R,8aR)-1,7,8-Trihydroxyoctahydroindolizin-6-yl butyrate Butanoic acid, (1S,6S,7S,8R,8aR)-octahydro-1,7,8-trihydroxy-6-indolizinyl ester Celgosivir

Description	Celgosivir (MBI 3253; MDL 28574; MX3253) is a novel α-glucosidase I inhibitor, an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope glycoproteins.[1]
Related Catalog	Signaling Pathways >> Anti-infection >> HCV Natural Products >> Alkaloid Research Areas >> Infection
Target	IC50: 16 and 47 umol/L (alpha-glucosidase I, Using plaque assay and a cytopathic assay)[2]
In Vitro	The quantity of THP-1 cells is 1 × 105 , cells were washed once with media and replaced with 500 μl with a serial 4-fold dilution starting from 200 μM or 50 μM.[3]
In Vivo	Celgosivir, stored at 100 mg/ml in PBS at 30 °C, were diluted with PBS before each dosing to obtain 1 mg/200 μl (50 mg/kg) or 0.2 mg/200 μl (10 mg/kg). [3]
References	[1]. Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs. 2009 Aug, 10(8):860-70. [2]. Whitby K et al. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for thetreatment of hepatitis C. Antivir Chem Chemother, 2004 May, 15(3):141-51. [3]. Satoru Watanabe，Kitti Wing-Ki Chan et al. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy. Antiviral Research, March 2016, Pages 10-19.

79831-76-8

121104-96-9

Literature: Liu; Hoekstra; King Tetrahedron Letters, 1990 , vol. 31, # 20 p. 2829 - 2832

79831-76-8

141-75-3

121104-96-9

Literature: Anderson, Wayne K.; Coburn, Robert A.; Gopalsamy, Ariamala; Howe, Trevor J. Tetrahedron Letters, 1990 , vol. 31, # 2 p. 169 - 170

Precursor 2
79831-76-8 141-75-3
DownStream 0